Elevidys’ Restricted Label Helps Sarepta Pressure Payers For Coverage Of DMD Gene Therapy

 
• By Derrick Gingery

Sarepta says the age limit in the indication could encourage swifter insurance coverage of the newly approved gene therapy for Duchenne muscular dystrophy so potential patients don't age out of the treatment window before they would be eligible for reimbursement.

Sarepta website
The initial accelerated approval of Elevidys restricted use to four- and five-year-old ambulatory DMD patients. • Source: Shutterstock

More from Market Access

More from Pink Sheet